Shenzhen Beimei Pharmaceutical
Specialized pharmaceutical developer of pediatric prescription medicines.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Series C | |
| Total Funding | 000k | ||
Related Content
Shenzhen Beimei Pharmaceutical Co., Ltd. is a pharmaceutical company founded in 2010 by Claire Wu that specializes in pediatric prescription medicines. Wu, who serves as CEO and General Manager, has over 20 years of experience in pharmaceutical marketing, sales, and R&D. The company aims to address the challenges of pediatric medication by developing high-quality, accurately-dosed, and palatable products for children.
Beimei Pharmaceutical operates with a dual strategy of in-house research and development combined with global collaboration through in-licensing and asset acquisitions. This approach allows the company to integrate R&D, manufacturing, and commercialization. The company's product pipeline includes over 40 pediatric drugs, with 7 already on the market, covering therapeutic areas such as dermatology, respiratory, gastroenterology, anti-infection, neurology, neonatal, and endocrinology. A key product is TWYNEO®, an FDA-approved cream for acne vulgaris, for which Beimei acquired the commercial rights in China and Israel in May 2024. Beimei has established a nearly 3,000-square-meter R&D center and has built proprietary technology platforms for pediatric sustained-release formulations, oral thin films, and topical transdermal gels.
The company's business model is centered on the development and commercialization of these specialized pediatric drugs. Revenue is generated through the sale of its approved products. Beimei Pharmaceutical has formed strategic long-term partnerships with major international pharmaceutical firms, including Hetero, Cipla, Dr. Reddy's, and Sol-Gel. The company is venture capital-backed, having completed multiple funding rounds, including Angel, Series A, B/B+, and C, with backing from institutions like Efung Capital and Nanshan Zhanxin Investment.
Keywords: pediatric pharmaceuticals, prescription drugs, drug development, pharmaceutical manufacturing, commercialization, in-licensing, asset acquisition, child health, dermatology, respiratory medicine, neurology, gastroenterology, anti-infection drugs, sustained-release formulation, oral thin film, taste-masking technology, TWYNEO, venture capital